WCM Investment Management LLC Increases Stake in Glaukos Co. (NYSE:GKOS)

WCM Investment Management LLC raised its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 45.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 99,155 shares of the medical instruments supplier's stock after buying an additional 31,084 shares during the period. WCM Investment Management LLC owned 0.18% of Glaukos worth $12,721,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Values First Advisors Inc. bought a new position in Glaukos during the 3rd quarter worth $25,000. GAMMA Investing LLC raised its position in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after acquiring an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Glaukos in the 2nd quarter valued at $187,000. Brighton Jones LLC bought a new position in shares of Glaukos during the 2nd quarter worth about $208,000. Finally, Procyon Advisors LLC acquired a new stake in Glaukos in the 3rd quarter valued at $210,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 2,275 shares of the firm's stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at approximately $14,198,425.93. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now directly owns 102,169 shares of the company's stock, valued at $14,198,425.93. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now owns 32,336 shares of the company's stock, valued at $4,225,345.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,525 shares of company stock valued at $2,142,029 in the last 90 days. Insiders own 6.40% of the company's stock.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of recent research reports. Needham & Company LLC raised their target price on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a report on Thursday, August 1st. Wells Fargo & Company raised their price target on shares of Glaukos from $135.00 to $145.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Truist Financial upped their price objective on shares of Glaukos from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. StockNews.com raised Glaukos from a "sell" rating to a "hold" rating in a research report on Monday, October 21st. Finally, BTIG Research lifted their target price on Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a research note on Wednesday, August 28th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and a consensus target price of $134.55.

Glaukos Price Performance

NYSE:GKOS traded up $0.61 during mid-day trading on Tuesday, hitting $143.65. 412,090 shares of the stock traded hands, compared to its average volume of 579,361. The business's 50-day moving average price is $130.07 and its 200 day moving average price is $121.35. The company has a market cap of $7.92 billion, a PE ratio of -47.64 and a beta of 1.02. The company has a quick ratio of 4.67, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $145.51.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. Glaukos's revenue for the quarter was up 23.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.50) EPS. On average, analysts expect that Glaukos Co. will post -1.96 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.